Market Overview

Cardiac Biomarker Market is projected to achieve a value of USD 13,370 Million in 2023, with a linear behavior in the market growth it is forecasted to achieve a value of USD 38,000 Million by 2033 with a CAGR of 11% during the forecast period 2023-2033.

Cardiac Biomarker are protein molecule that are released into the blood after heart damage or intense heart stress. These biomarkers act as a potential indication tool to find out the various cardiovascular diseases (CVD) such as myocardial infarction, acute coronary syndrome, cardiac ischemia and congestive heart failure. The test uses to determine the risk and condition of patients associate with such disease is Cardiac biomarker tests.

Cardiac Biomarkers tests are performed when the patient suffers from chest pain. Troponin, creatine kinase-muscle/brain (CK-MB), B-type natriuretic peptide (BNP), high-sensitivity C-reactive protein (hs-CRP), this are the cardiac biomarkers that are tested for cardiovascular diseases. Myocardial muscle creatine kinase (CK-MB), troponin I and T, myoglobin, brain natriuretic peptide (BNPs), ischemia modified albumin (IMA), these are the Cardiac biomarkers that are widely used as an integrated diagnostic approach for cardiovascular diseases., thereby providing a smoother scenario for overall Cardiac biomarker market growth.

Market Scope

 Market Dynamics

Cardiac biomarker market is driven by many factors such as the rising burden of cardiovascular diseases, increasing research and development investments and technological advances in cardiac biomarkers. For instance, according to the British Heart Foundation data published in January 2022 reported that in 2021, the most common heart conditions affected globally were ischemic heart disease, peripheral arterial (vascular) disease (110 million), stroke (100 million), and atrial fibrillation (60 million).

Furthermore, the technologically advanced cardiac biomarkers launched by various market players is also anticipated to enhance the growth the Cardiac biomarker market. For instance, in April 2021, Roche launched a series of five new intended uses for two key cardiac biomarkers using the Elecsys technology, i.e., N-terminal pro-brain natriuretic peptide test (NT-proBNP) and high-sensitive cardiac troponin T (cTnT-hs).

COVID-19 pandemic impact is expected to remain positive for the cardiac biomarkers testing industry. Increasing the number of patients having preexisting history of cardiovascular diseases with COVID 19. As these patients with existing medical conditions like cardiovascular disease suffering from COVID-19 are more heart attack. Moreover, it was found that the troponil level is higher significant in COVID 19 patients who die or critical in condition.

Moreover, emerging markets such as India and china offers a significant growth in cardiac diagnosing market. For Instance, According to IHA (Indian Heart Association) 2019, India accountable for 60% of global heart disease burden, among them 50% of all heart attacks in Indian men under the age of 50 years. The increasing burden of cardiovascular diseases in growing countries which drive the demand for early disease diagnosis increasing the adoption of cardiac marker testing products.

Market Type Analysis

The cardiac biomarker market is Categories into Troponin, CK-MB, Myoglobin, BNP and NT-proBNP. The Troponin segment accounts for the largest share of around 35% of the market in 2022. The significant growth can be attributed to factors such as specificity, diagnostic efficiency, and accurate predictive detection of cardiac events when compared to other tests. The increasing prevalence of MI (myocardial infarction) and stroke all over the world further boosts market growth

BNP and NT-proBNP segment is expected to grow rapidly due to its significantly use in detecting heart damage and stress. Companies are entering the market with this test to generate more  sale. For instance, in June 2022, LumiraDx Limited announced the diversification of its portfolio with a CE Mark for its D-Dimer test and NT-proBNP test. The commercialization of the latter is projected by the end of 2022, which is expected to facilitate clinical decision-making.

Market Application Analysis

By Application, the Cardiac biomarker market is Categories into Acute Coronary Syndrome, Myocardial Infarction (MI). The Myocardial Infarction segment accounts for the largest share of around 53% of the market in 2022.

Myocardial infarction is a stage of dyeing heart muscles due a lack of oxygen-rich blood flow to the heart muscle. I biomarkers and Cardiac Troponin T tests have emerged as the prime diagnostic methods for diagnosing the disease.

Market End User Analysis

By End-user, the Cardiac biomarker market is Categories into Hospital, speciality Clinics. The Hospital segment accounts for the largest share of around 56% of the market in 2022. Rising investment in healthcare and increasing hospital facility in developed and developing country are major factor to drive the segment. Increasing prevalence of cardiovascular diseases and COVID-19 is one more additional factor which helps to dominate the segment.

However, specialty clinics and number of other services like modern testing labs and ambulatory services in developing countries are anticipated to drive the Cardiac Biomarker Market.

Market Regional Analysis

North America dominate the Cardiac Biomarker market with the highest revenue generating market with share of more than 42%. Well established healthcare facility, availability of services and products, high expenditure on R&D are the key driving factor of the region. For instance, according to the American College of Cardiology Foundation, in 2019 it is estimated that about 1.05 million patients were suffering from coronary disorders in the United States alone.

Asia-Pacific is expected to expand the higher growth with highest CAGR in forecasted year. The factors behind that are increasing investment in healthcare sector, increasing awareness about the cardiovascular diseases, after COVID19 increasing the cardiac testing facility in the region. For instance, in January 2023, Cipla Inc, an Indian multinational pharmaceutical company, launched a diagnostic device called Cippoint, which offers a point-of-care testing solution for various health conditions

Moreover, Europe is the fastest growing Cardiac Biomarker market in forecasting year. Rising prevalence of acute coronary syndrome and myocardial infarction leading to the increasing demand to improve diagnostic facility, government funding for research and targeted diseases and healthcare expenditure.

Latin America and Middle East & Africa are expected to grow at a moderate level because of slower adoption of technologically advanced solutions and lack of awareness among the population towards tests for cardiac biomarker industry.

Competitive Analysis

The Cardiac Biomarker market is dominated by a few large companies, such as F. Hoffmann-La Roche AG, Abbott, Siemens AG, Creative Diagnostics, Beckman Coulter, Inc., Thermo Fisher Scientific Inc., bioMérieux SA, Others.

There are some of the key trends that are shaping the competitive landscape of the Cardiac Biomarker market.

April 2021 –Siemens AG. announced that they received CE Mark approval for their point-of-care Atellica VTLiPatient-Side Immunoassay Analyzer, a high sensitivity troponin I test. The approved device detects protein biomarkers for acute myocardial infraction.

April 2021 – F. Hoffmann-La Roche Ltd announced the launch of five new applications for their key cardiac biomarkers in combination with their Elecsys technology. These biomarkers have been proved to be successful managing cardiovascular diseases and can help clinicians to diagnose heart attacks and manage heart failures in patients.

Sept 2019 -Abbott Laboratories received FDA approval for the ARCHITECT STAT High sensitivity Troponin-I blood test used in the diagnosis of myocardial infraction.

By Type

·         Troponin

·         CK-MB

·         Myoglobin

·         BNP and NT-proBNP

By Application

·         Acute Coronary Syndrome

·         Myocardial Infarction

By End-User

·         Hospital

·         speciality Clinics